Genzyme Charitable Foundation

Genzyme Charitable Foundation

The Genzyme Charitable Foundation was formed in 1997 as the philanthropic vehicle for Genzyme Corporation, the Cambridge-born biotechnology pioneer founded by Sheridan Snyder that became a global rare-disease powerhouse. When Sanofi S.A. acquired Genzyme for roughly $20.1 billion in 2011, the foundation did not dissolve — it was absorbed as a corporate-sponsored operating foundation, now run out of Sanofi's US headquarters in Morristown, New Jersey. William Sibold, a Sanofi executive vice president, serves as the foundation's president, continuing a governance model that embeds the foundation's leadership inside the parent company's commercial organization rather than at arm's length. The foundation pursues a hybrid grantmaking strategy that few corporate philanthropies replicate. On the cash side, it distributes millions annually in grants to organizations working at the intersection of science education, healthcare access, and community development. One sustained commitment is the STEM Mentor Program at MassBay Community College, a long-term partnership that funds early-career science exposure for underrepresented students. On the in-kind side, the foundation operates what is effectively a pharmaceutical patient-assistance program, distributing prescription medications to individuals who lack prescription drug coverage — leveraging Sanofi's global distribution centers to deliver product directly into communities across the United States and select international markets. Asset scale is modest by institutional foundation standards. Altss research places total assets at approximately $75 million, though the foundation does not publicly disclose a formal AUM figure. The treasury function sits inside Sanofi's corporate finance apparatus; Debora C. Pellicano serves as both the foundation's treasurer and a director, further entrenching operational oversight within the parent company. The foundation is a known member of Philanthropy Massachusetts, the regional association of grantmakers, signaling at least periodic engagement with the broader institutional philanthropy community in New England. September 2023: The foundation continued its long-running MassBay Community College STEM Mentor Program grant cycle (per public record). The Genzyme Charitable Foundation's structural differentiator is its in-kind pharmaceutical access program, which transforms corporate manufacturing capacity — and the carrying cost of unsold or donated inventory — into a direct health intervention. Most corporate foundations write checks. This one distributes actual medicine. That product-donation model binds the foundation's grantmaking to Sanofi's operational footprint, creating a sourcing dynamic where philanthropic impact scales with the parent company's production decisions rather than with AUM growth alone.